Sox2 Is an Androgen Receptor-Repressed Gene That Promotes Castration-Resistant Prostate Cancer

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Kregel, Steven ^a   Kiriluk, Kyle J ^a   Rosen, Alex M ^a   Cai, Yi ^a   Reyes, Edwin E ^a   Otto, Kristen B ^a   Tom, Westin ^a   Paner, Gladell P ^a   Szmulewitz, Russell Z ^a   Vander Griend, Donald J ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; FIBROBLAST GROWTH FACTOR 5; TRANSCRIPTION FACTOR SOX2;

ARTICLE; CARCINOGENESIS; CASTRATION; CELL GROWTH; EMBRYONIC STEM CELL; EPITHELIUM CELL; GLEASON SCORE; HUMAN; HUMAN CELL; IN VIVO STUDY; METASTASIS; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; SRY GENE;

ANDROGEN ANTAGONISTS; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; EMBRYONIC STEM CELLS; EPITHELIAL CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, NUDE; NEOPLASM METASTASIS; ORCHIECTOMY; PHENYLTHIOHYDANTOIN; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; REPRESSOR PROTEINS; RNA, MESSENGER; SIGNAL TRANSDUCTION; SOXB1 TRANSCRIPTION FACTORS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 84872241633     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0053701     Document Type: Article

References (67)

1. Huggins C, Stevens RE, Hodges CV, (1941) Studies on Prostate Cancer: II. The Effects of Castration on Advanced Carcinoma of the Prostate Gland. Archives of Surgery 43: 209-223.
2. Isaacs JT, Isaacs WB, (2004) Androgen receptor outwits prostate cancer drugs. Nat Med 10: 26-27.
3. Singh P, Uzgare A, Litvinov I, Denmeade SR, Isaacs JT, (2006) Combinatorial androgen receptor targeted therapy for prostate cancer. Endocr Relat Cancer 13: 653-666.
4. Takahashi K, Yamanaka S, (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126: 663-676.
5. Rodriguez-Pinilla SM, Sarrio D, Moreno-Bueno G, Rodriguez-Gil Y, Martinez MA, et al. (2007) Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer. Mod Pathol 20: 474-481.
6. Karoubi G, Gugger M, Schmid R, Dutly A, (2009) OCT4 expression in human non-small cell lung cancer: implications for therapeutic intervention. Interact Cardiovasc Thorac Surg 8: 393-397.
7. Jeter CR, Badeaux M, Choy G, Chandra D, Patrawala L, et al. (2009) Functional evidence that the self-renewal gene NANOG regulates human tumor development. Stem Cells 27: 993-1005.
8. Chambers I, Tomlinson SR, (2009) The transcriptional foundation of pluripotency. Development 136: 2311-2322.
9. Ezeh UI, Turek PJ, Reijo RA, Clark AT, (2005) Human embryonic stem cell genes OCT4, NANOG, STELLAR, and GDF3 are expressed in both seminoma and breast carcinoma. Cancer 104: 2255-2265.
10. Ye F, Zhou C, Cheng Q, Shen J, Chen H, (2008) Stem-cell-abundant proteins Nanog, Nucleostemin and Musashi1 are highly expressed in malignant cervical epithelial cells. BMC Cancer 8: 108.
11. Chiou SH, Yu CC, Huang CY, Lin SC, Liu CJ, et al. (2008) Positive correlations of Oct-4 and Nanog in oral cancer stem-like cells and high-grade oral squamous cell carcinoma. Clin Cancer Res 14: 4085-4095.
12. Zhang S, Balch C, Chan MW, Lai HC, Matei D, et al. (2008) Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 68: 4311-4320.
13. Gu G, Yuan J, Wills M, Kasper S, (2007) Prostate Cancer Cells with Stem Cell Characteristics Reconstitute the Original Human Tumor In vivo. Cancer Res 67: 4807-4815.
14. Guzman-Ramirez N, Voller M, Wetterwald A, Germann M, Cross NA, et al. (2009) In vitro propagation and characterization of neoplastic stem/progenitor-like cells from human prostate cancer tissue. Prostate 69: 1683-1693.
15. Liu T, Xu F, Du X, Lai D, Liu T, et al. (2010) Establishment and characterization of multi-drug resistant, prostate carcinoma-initiating stem-like cells from human prostate cancer cell lines 22RV1. Mol Cell Biochem 340: 265-273.
16. Gibbs CP, Kukekov VG, Reith JD, Tchigrinova O, Suslov ON, et al. (2005) Stem-like cells in bone sarcomas: implications for tumorigenesis. Neoplasia 7: 967-976.
17. Yuan P, Kadara H, Behrens C, Tang X, Woods D, et al. (2010) Sex determining region Y-Box 2 (SOX2) is a potential cell-lineage gene highly expressed in the pathogenesis of squamous cell carcinomas of the lung. PLOS One 5: e9112.
18. Maier S, Wilbertz T, Braun M, Scheble V, Reischl M, et al. (2011) SOX2 amplification is a common event in squamous cell carcinomas of different organ sites. Hum Pathol 42 (8): 1078-1088.
19. Rizzino A, (2009) Sox2 and Oct-3/4: A Versatile Pair of Master Regulators that Orchestrate the Self-renewal and Pluripotency of Embryonic Stem Cells by Functioning as Molecular Rheostats. Wiley Interdiscip Rev Syst Biol Med 1: 228-236.
20. Hussenet T, Dali S, Exinger J, Monga B, Jost B, et al. (2010) SOX2 is an oncogene activated by recurrent 3q26.3 amplifications in human lung squamous cell carcinomas. PLOS One 5: e8960.
21. Boyer LA, Lee TI, Cole MF, Johnstone SE, Levine SS, et al. (2005) Core transcriptional regulatory circuitry in human embryonic stem cells. Cell 122: 947-956.
22. Ugolkov AV, Eisengart LJ, Luan C, Yang XJ, (2010) Expression analysis of putative stem cell markers in human benign and malignant prostate. Prostate 71: 18-25.
23. Jia X, Li X, Xu Y, Zhang S, Mou W, et al. (2011) SOX2 promotes tumorigenesis and increases the anti-apoptotic property of human prostate cancer cell. J Mol Cell Biol 3: 230-238.
24. Markert EK, Mizuno H, Vazquez A, Levine AJ, (2011) Molecular classification of prostate cancer using curated expression signatures. Proc Natl Acad Sci U S A 108: 21276-21281.
25. Chen JL, Li J, Kiriluk K, Rosen A, Paner G, et al. (2012) Deregulation of a Hox Protein Regulatory Network Spanning Prostate Cancer Initiation and Progression. Clin Cancer Res 18: 4291-4302.
26. Litvinov IV, Vander Griend DJ, Xu Y, Antony L, Dalrymple SL, et al. (2006) Low-Calcium Serum-Free Defined Medium Selects for Growth of Normal Prostatic Epithelial Stem Cells. Cancer Res 66: 8598-8607.
27. D'Antonio JM, Vander Griend DJ, Antony L, Ndikuyeze G, Dalrymple SL, et al. (2010) Loss of androgen receptor-dependent growth suppression by prostate cancer cells can occur independently from acquiring oncogenic addiction to androgen receptor signaling. PLOS One 5: e11475.
28. Litvinov IV, Vander Griend DJ, Xu Y, Antony L, Dalrymple SL, et al. (2006) Low-calcium serum-free defined medium selects for growth of normal prostatic epithelial stem cells. Cancer Res 66: 8598-8607.
29. Maherali N, Ahfeldt T, Rigamonti A, Utikal J, Cowan C, et al. (2008) A high-efficiency system for the generation and study of human induced pluripotent stem cells. Cell Stem Cell 3: 340-345.
30. Gao J, Arnold JT, Isaacs JT, (2001) Conversion from a paracrine to an autocrine mechanism of androgen-stimulated growth during malignant transformation of prostatic epithelial cells. Cancer Res 61: 5038-5044.
31. Vander Griend DJ, Karthaus WK, Dalrymple S, Meeker AK, De Marzo AM, et al. (2008) The Role of CD133 in Normal Human Prostate Stem Cells and Malignant Cancer Initiating Cells. Cancer Res 68: 9703-9711.
32. Uzgare AR, Xu Y, Isaacs JT, (2004) In vitro culturing and characteristics of transit amplifying epithelial cells from human prostate tissue. J Cell Biochem 91: 196-205.
33. Wang Q, Li W, Zhang Y, Yuan X, Xu K, et al. (2009) Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 138: 245-256.
34. Isaacs JT, (2008) Prostate stem cells and benign prostatic hyperplasia. Prostate 68: 1025-1034.
35. Goldstein AS, Huang J, Guo C, Garraway IP, Witte ON, (2010) Identification of a cell of origin for human prostate cancer. Science 329: 568-571.
36. Ling MT, Chan KW, Choo CK, (2001) Androgen induces differentiation of a human papillomavirus 16 E6/E7 immortalized prostate epithelial cell line. J Endocrinol 170: 287-296.
37. Whitacre DC, Chauhan S, Davis T, Gordon D, Cress AE, et al. (2002) Androgen induction of in vitro prostate cell differentiation. Cell Growth Differ 13: 1-11.
38. Berger R, Febbo PG, Majumder PK, Zhao JJ, Mukherjee S, et al. (2004) Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells. Cancer Res 64: 8867-8875.
39. Vander Griend DJ, D'Antonio J, Gurel B, Antony L, Demarzo AM, et al. (2010) Cell-autonomous intracellular androgen receptor signaling drives the growth of human prostate cancer initiating cells. Prostate 70: 90-99.
40. van Bokhoven A, Varella-Garcia M, Korch C, Johannes WU, Smith EE, et al. (2003) Molecular characterization of human prostate carcinoma cell lines. Prostate 57: 205-225.
41. Walker E, Ohishi M, Davey RE, Zhang W, Cassar PA, et al. (2007) Prediction and testing of novel transcriptional networks regulating embryonic stem cell self-renewal and commitment. Cell Stem Cell 1: 71-86.
42. Chen L, Daley GQ, (2008) Molecular basis of pluripotency. Hum Mol Genet 17: R23-27.
43. Jeter CR, Liu B, Liu X, Chen X, Liu C, et al. (2011) NANOG promotes cancer stem cell characteristics and prostate cancer resistance to androgen deprivation. Oncogene 30: 3833-3845.
44. Denmeade SR, Litvinov I, Sokoll LJ, Lilja H, Isaacs JT, (2003) Prostate-specific antigen (PSA) protein does not affect growth of prostate cancer cells in vitro or prostate cancer xenografts in vivo. Prostate 56: 45-53.
45. Yu J, Mani RS, Cao Q, Brenner CJ, Cao X, et al. (2010) An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 17: 443-454.
46. Urbanucci A, Sahu B, Seppala J, Larjo A, Latonen LM, et al. (2012) Overexpression of androgen receptor enhances the binding of the receptor to the chromatin in prostate cancer. Oncogene 31: 2153-2163.
47. Kim JH, Dhanasekaran SM, Prensner JR, Cao X, Robinson D, et al. (2011) Deep sequencing reveals distinct patterns of DNA methylation in prostate cancer. Genome Res 21: 1028-1041.
48. Lin B, Wang J, Hong X, Yan X, Hwang D, et al. (2009) Integrated expression profiling and ChIP-seq analyses of the growth inhibition response program of the androgen receptor. PLOS One 4: e6589.
49. Chen Y, Clegg NJ, Scher HI, (2009) Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol 10: 981-991.
50. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, et al. (2009) Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324: 787-790.
51. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, et al. (2010) Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 375: 1437-1446.
52. Wu TT, Sikes RA, Cui Q, Thalmann GN, Kao C, et al. (1998) Establishing human prostate cancer cell xenografts in bone: induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines. Int J Cancer 77: 887-894.
53. Craft N, Shostak Y, Carey M, Sawyers CL, (1999) A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 5: 280-285.
54. Denmeade SR, Sokoll LJ, Dalrymple S, Rosen DM, Gady AM, et al. (2003) Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models. Prostate 54: 249-257.
55. Tepper CG, Boucher DL, Ryan PE, Ma AH, Xia L, et al. (2002) Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. Cancer Res 62: 6606-6614.
56. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ, (2005) Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65: 10946-10951.
57. Gou D, Weng T, Wang Y, Wang Z, Zhang H, et al. (2007) A novel approach for the construction of multiple shRNA expression vectors. J Gene Med 9: 751-763.
58. Chen X, Xu H, Yuan P, Fang F, Huss M, et al. (2008) Integration of external signaling pathways with the core transcriptional network in embryonic stem cells. Cell 133: 1106-1117.
59. Bass AJ, Watanabe H, Mermel CH, Yu S, Perner S, et al. (2009) SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet 41: 1238-1242.
60. Chen Y, Shi L, Zhang L, Li R, Liang J, et al. (2008) The molecular mechanism governing the oncogenic potential of SOX2 in breast cancer. J Biol Chem 283: 17969-17978.
61. Huang P, Qiu J, Li B, Hong J, Lu C, et al. (2011) Role of Sox2 and Oct4 in Predicting Survival of Hepatocelluar Carcinoma Patients after Hepatectomy. Clin Biochem 44: 582-589.
62. Wilbertz T, Wagner P, Petersen K, Stiedl AC, Scheble VJ, et al. (2011) SOX2 gene amplification and protein overexpression are associated with better outcome in squamous cell lung cancer. Mod Pathol 24: 944-953.
63. Thomson M, Liu SJ, Zou LN, Smith Z, Meissner A, et al. (2011) Pluripotency factors in embryonic stem cells regulate differentiation into germ layers. Cell 145: 875-889.
64. Wang Z, Oron E, Nelson B, Razis S, Ivanova N, (2012) Distinct lineage specification roles for NANOG, OCT4, and SOX2 in human embryonic stem cells. Cell Stem Cell 10: 440-454.
65. Christophersen NS, Helin K, (2010) Epigenetic control of embryonic stem cell fate. J Exp Med 207: 2287-2295.
66. Hanahan D, Weinberg RA, (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.
67. Stolzenburg S, Rots MG, Beltran AS, Rivenbark AG, Yuan X, et al. (2012) Targeted silencing of the oncogenic transcription factor SOX2 in breast cancer. Nucleic Acids Res 40: 6725-6740.